Last reviewed 2026-04-23 · How we verify

Romidepsin + CHOP

Romidepsin inhibits histone deacetylases to promote cancer cell death, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for multi-modal lymphoma treatment.

Romidepsin inhibits histone deacetylases to promote cancer cell death, combined with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, prednisone) for multi-modal lymphoma treatment. Used for Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL).

At a glance

Mechanism of action

Romidepsin is a histone deacetylase (HDAC) inhibitor that induces apoptosis in T-cell lymphomas by altering gene expression through chromatin remodeling. CHOP is a standard multi-agent chemotherapy regimen. The combination leverages romidepsin's targeted epigenetic mechanism with conventional chemotherapy to improve efficacy in lymphoid malignancies.

Approved indications

• Peripheral T-cell lymphoma (PTCL)
• Cutaneous T-cell lymphoma (CTCL)

Common side effects

• Myelosuppression
• Nausea and vomiting
• Fatigue
• Infection
• Cardiac arrhythmias
• Tumor lysis syndrome

Key clinical trials

• Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma (PHASE3)
• A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Romidepsin + CHOP CI brief — competitive landscape report
• Romidepsin + CHOP updates RSS · CI watch RSS
• The Lymphoma Academic Research Organisation portfolio CI